Aerie Pharmaceuticals Inc (NASDAQ:AERI) was the recipient of some unusual options trading on Wednesday. Stock investors bought 1,074 call options on the stock. This is an increase of 1,031% compared to the average daily volume of 95 call options.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at $59.35 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24. The stock has a market capitalization of $2,180.00, a P/E ratio of -17.72 and a beta of 1.11. Aerie Pharmaceuticals has a 52 week low of $37.80 and a 52 week high of $66.60.
A number of large investors have recently added to or reduced their stakes in AERI. Ameritas Investment Partners Inc. raised its stake in Aerie Pharmaceuticals by 11.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after buying an additional 275 shares during the period. Quantbot Technologies LP raised its stake in Aerie Pharmaceuticals by 792.5% in the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after buying an additional 2,647 shares during the period. BNP Paribas Arbitrage SA raised its stake in Aerie Pharmaceuticals by 2,711.4% in the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after buying an additional 3,579 shares during the period. Amalgamated Bank bought a new stake in Aerie Pharmaceuticals in the second quarter valued at approximately $204,000. Finally, Great West Life Assurance Co. Can raised its stake in Aerie Pharmaceuticals by 65.0% in the third quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock valued at $204,000 after buying an additional 1,639 shares during the period.
Several research analysts recently commented on AERI shares. Cowen reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Mizuho reissued a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Monday, October 2nd. Canaccord Genuity reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, September 22nd. Needham & Company LLC reissued a “buy” rating and set a $65.00 price target on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Finally, JMP Securities set a $68.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $72.00.
ILLEGAL ACTIVITY WARNING: This article was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://transcriptdaily.com/2018/01/06/investors-purchase-high-volume-of-aerie-pharmaceuticals-call-options-aeri.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.